category guide

How to Choose Orthopedic Implants

May 1, 2026· 12 min read· AI-generated

How to Choose Orthopedic Implants

A procurement guide for hospital supply chain teams, ASC administrators, and value analysis committees navigating implant selection, platform dependencies, and episode-cost control.

What this is and who buys it

Orthopedic implants are surgically inserted biocompatible devices designed to replace, stabilize, or reinforce damaged bones and joints. The materials list reads like an engineering specification sheet: titanium alloy (Ti-6Al-4V) for most load-bearing stems and screws, cobalt-chromium-molybdenum (CoCrMo) for femoral heads and knee femoral components, ultra-high-molecular-weight polyethylene (UHMWPE) for bearing liners, and ceramic (alumina or zirconia-toughened alumina) as an alternative bearing surface. The category spans joint reconstruction—total hip arthroplasty (THA), total knee arthroplasty (TKA), total shoulder arthroplasty (TSA)—spinal fixation systems, and trauma fixation hardware including intramedullary nails and locking plates.

The buying universe is wide but concentrated at the top. Acute care hospitals command roughly 63.7% of orthopedic implant end-use by revenue, driven by inpatient surgical volume and the case complexity that inpatient settings absorb [S6]. The fastest-growing buyer segment is ambulatory surgery centers, which are absorbing lower-acuity primary arthroplasty under payer pressure to shift cases out of the hospital setting—a trend accelerated by CMS removing TKA from the inpatient-only list in 2018. Orthopedic specialty hospitals and high-volume spine centers round out the primary procurement audience, with GPO purchasing officers and value analysis committees (VACs) serving as the institutional counterweight to surgeon-driven implant selection.

What makes this category distinctive—and genuinely difficult to procure well—is the intersection of surgeon preference, bundled payment economics, and capital platform lock-in. Unlike a CT scanner or a ventilator, an orthopedic implant purchase decision is rarely made by supply chain alone. It involves the operating surgeon, the VAC, the sterile processing department, the C-suite (when a robotic platform is attached to the implant contract), and increasingly the finance team tracking episode-of-care costs under DRG 469/470.

Key decision factors

Implant-level cost relative to total episode cost is the factor supply chain teams most often underestimate in isolation. A 2024 systematic review published in the Journal of Orthopaedic Business put the average TKA implant construct at $5,336 ± $1,671, accounting for approximately 22% of total TKA episode cost [S2]. For THA, the construct figure is in a similar range. That fraction is large enough to move the needle meaningfully under bundled payment models, which is why benchmarking each implant line against GPO contract tiers—before any volume commitment—is a non-negotiable first step, not a post-signature audit.

Material and bearing surface selection deserves more scrutiny than it typically receives in a standard vendor presentation. CoCrMo femoral heads paired with UHMWPE liners remain the workhorse combination for total hip arthroplasty, but highly cross-linked UHMWPE has largely replaced conventional polyethylene to reduce wear debris. Ceramic-on-ceramic and ceramic-on-UHMWPE configurations carry lower wear rates and are often preferred for younger, more active patients, at a cost premium. The metal-on-metal (MoM) bearing history is instructive: FDA safety communications beginning in 2011 flagged elevated corrosion and adverse local tissue reaction risks for MoM hips, leading to multiple recalls and a de facto market exit for that bearing class. Procurement teams should validate that bearing surface selection aligns with the patient population's age distribution, activity level, and BMI profile—factors that directly drive long-term wear and revision risk.

510(k) clearance status and predicate traceability matter more than many procurement teams realize. The vast majority of orthopedic implants are Class II devices cleared through the 510(k) pathway under 21 CFR Part 888 [S1]. The practical implication: a device reaches market by demonstrating substantial equivalence to a predicate—not by conducting independent clinical trials. That means the predicate device's safety record is load-bearing. If a vendor cannot produce the 510(k) clearance number and predicate citation on request, or if the predicate device has a troubled recall history, that is a disqualifying condition, not a minor administrative gap.

Robotic platform lock-in is arguably the most consequential structural decision in modern orthopedic implant procurement. Several major implant systems are designed with platform-exclusive compatibility: a robotic-guided TKA on one manufacturer's system will require that manufacturer's implant, full stop. Selecting a robotic-assisted surgery program is therefore also selecting an implant brand, often for the life of the capital equipment—typically 7–10 years. Facilities should model robotic capital costs, annual service contract costs, and procedural volume thresholds (commonly cited at 150–300+ cases per year to justify per-case economics) before allowing robotic platform preference to drive an implant contract.

Surgeon preference variation and VAC standardization represent the single highest-leverage procurement opportunity in the entire category. Research has documented that physician preference variation alone accounts for 36–61% of total knee and hip implant cost variation across hospitals [S5]. Standardizing to one or two implant systems per joint type through a structured VAC process—supported by registry-based outcome data rather than manufacturer-supplied literature—consistently delivers 15–25% cost reductions in comparable institutions. The resistance is real, but the financial and operational case for standardization is overwhelming.

Consignment inventory and loaner set management are operational factors that become financial factors quickly. Most implant vendors supply reusable instrument sets on consignment, meaning the hospital sterilizes, tracks, and is liable for the trays without owning them. Each tray cycle must comply with ANSI/AAMI ST79 and manufacturer instructions for use. Multi-vendor loaner environments place compounding demands on sterile processing department throughput—a constraint that is easy to underestimate during contract negotiations and expensive to discover after a case cancellation.

Revision construct compatibility is a factor that surfaces only when it becomes urgent—and at that point, the procurement leverage is gone. Verify before contracting that primary implant systems are backward-compatible with the same vendor's revision components. Revision arthroplasty implants are significantly more expensive than primary constructs and carry longer lead times; emergency procurement from a different vendor is operationally and clinically fraught.

Post-market surveillance and registry participation provide the one data source that manufacturer literature cannot replicate: independent long-term survivorship. The American Joint Replacement Registry (AJRR) collects outcome and revision data across participating institutions and publishes annual reports that disaggregate revision rates by implant system, bearing surface, and fixation method. If a vendor cannot point to AJRR data (or an equivalent national registry such as the Australian Orthopaedic Association National Joint Replacement Registry) for their primary implant lines, the durability claims in their sales materials are unverifiable.

What it costs

Orthopedic implant pricing is notoriously opaque. GPO contract pricing is confidential, direct negotiation pricing varies enormously by volume tier, and publicly available list prices are rarely transaction prices. The figures below represent approximate construct-level ranges based on available published data; actual contracted pricing at your facility will depend on GPO affiliation, annual case volume, and vendor concentration commitments. If a vendor cannot or will not benchmark their pricing against GPO peers, treat that as a red flag.

Entry tier ($1,000–$4,999 per construct): Primarily trauma fixation hardware—locking plates, intramedullary nails, cephalomedullary devices—and basic joint implants; appropriate for high-volume, standardized programs with strong GPO positioning.
Mid tier ($5,000–$12,000 per construct): The core range for primary total hip and knee arthroplasty constructs; the $5,336 TKA average [S2] sits in the lower half of this band. Most VAC negotiation targets land here.
Premium tier ($12,000–$22,000+ per construct): Includes complex revision arthroplasty constructs, patient-matched (3D-printed) implants, total disc replacement devices, and implants requiring PMA-level regulatory approval. Patient-specific implants carry an additional 30–60% cost premium over standard catalog and require 4–6 week lead times [S8].

Common use cases

The setting in which an implant is used shapes inventory strategy, vendor selection, and regulatory scrutiny as much as the implant category itself. A Level I trauma center managing polytrauma at 2 a.m. has fundamentally different procurement requirements than an ASC running a scheduled primary TKA program on Tuesday mornings.

Acute care hospital inpatient OR: Primary volume for THA, TKA, TSA, complex spinal fusion (pedicle screw/interbody cage constructs), and polytrauma fixation; the setting where implant standardization programs deliver the largest absolute dollar impact.
Ambulatory surgery centers: Growing site-of-care for lower-acuity primary arthroplasty and outpatient lumbar spine procedures; lean implant inventories, predictable case mix, and payer preference for cost-efficient episodes make standardization more achievable here than in acute care.
Trauma centers (Level I/II): High and unpredictable utilization of fracture fixation hardware—intramedullary nails, locking plates, cephalomedullary devices—requiring broader implant inventory and reliable next-day restocking commitments from vendors.
Spine surgery centers: Dedicated pedicle screw systems, TLIF/LLIF/ALIF interbody fusion cages, and cervical disc replacement devices, increasingly integrated with robotic guidance platforms that carry their own implant compatibility implications.

Regulatory and compliance

The regulatory framework for orthopedic implants is anchored in 21 CFR Part 888, which classifies most standard hip, knee, and spinal fixation implants as Class II devices subject to special controls and 510(k) clearance [S1]. Novel joint designs, hip resurfacing implants with modified metallic surfaces, and total disc replacement devices may require Premarket Approval (PMA) under Class III, which demands clinical trial evidence—a meaningful distinction when evaluating a newer implant system against an established one. Every implant purchase should begin with a 510(k) or PMA number lookup in FDA's public database; devices that cannot be verified there should not enter a facility's supply chain.

Beyond clearance classification, several standards govern the implant lifecycle from manufacturing through in-facility handling. ISO 10993-1 establishes the biological evaluation framework for implant materials, and procurement teams should request a biological evaluation summary for any new alloy formulation or bearing surface—particularly relevant when a vendor introduces a reformulated polymer or changes a surface coating. ISO 19227:2018 specifies cleanliness requirements for orthopedic implants at the manufacturing level [S4], and ISO 13485:2016 governs the quality management system of the manufacturing facility itself; a lapsed ISO 13485 certificate is an early supply-chain risk signal. At the facility level, ASTM F565-26 provides the standard practice for care and handling of implants and instruments [S7], directly informing OR staff training and loaner tray protocols. Finally, all implants must carry UDI labels per 21 CFR Part 830 and be registered in FDA's GUDID database—a compliance requirement that also enables the implant traceability that The Joint Commission expects and that becomes critical in the event of a field safety corrective action.

Service, training, and total cost of ownership

Unlike capital equipment, permanent orthopedic implants carry no facility-level calibration obligation after implantation. The total cost of ownership conversation is therefore not about preventive maintenance schedules for the implant itself—it's about the instrument ecosystem and the operational infrastructure surrounding it.

The most underestimated ongoing cost is loaner instrument set management. A vendor supplying instrument trays on consignment is effectively outsourcing tray ownership to the hospital's sterile processing department. Each tray requires full decontamination, inspection, assembly, and sterilization per ANSI/AAMI ST79 before every use. Facilities expanding from two to four implant vendors without a corresponding SPD capacity assessment routinely discover the bottleneck through case delays, not through planning. If the SPD cannot turn trays within the OR scheduling window, the implant savings on paper disappear in overtime and case cancellations in practice.

For robotic-platform-dependent implant programs, the service and training dimension is substantial. OR teams typically require 4–8 weeks of workflow training before achieving efficient robotic-assisted case throughput, and the robotic capital equipment itself is subject to manufacturer-scheduled preventive maintenance under IEC 60601-1 for electrically powered surgical equipment. Service contracts for robotic platforms run $80,000–$200,000 annually depending on coverage level (pricing is not publicly standardized and varies by vendor negotiation)—a cost that should be factored into the per-case implant economics before the platform decision is finalized.

The in-body lifespan of primary hip and knee arthroplasty implants is engineered at 15–20+ years for appropriately selected patients, a figure supported by registry survivorship data. Trauma fixation hardware may be removed after fracture healing, typically 6–18 months post-implantation. Vendor representative support for complex primary and revision cases is standard under most implant contracts; facilities should negotiate clear written policies on OR presence scope, consistent with CMS and Joint Commission requirements for non-employee OR personnel, before cases begin rather than after a conflict arises.

Red flags to watch for

Any implant selection that bypasses the Value Analysis Committee without documented clinical justification should stop at the VAC chair's desk. Sole-source physician preference arrangements that lack a formal equivalency review expose the facility to OIG scrutiny under anti-kickback statute analysis of vendor-surgeon financial relationships—and eliminate the negotiating leverage that volume commitments create.

Pricing agreements that prohibit benchmarking against GPO peers or reference databases are structurally disadvantageous. Most-favored-nation clauses and transparency on volume rebate thresholds are standard asks in a well-structured RFP; if a vendor declines both, the pricing architecture is designed to your disadvantage, not theirs.

Vendors without independent long-term survivorship data from a national registry—AJRR or an international equivalent—cannot substantiate the durability claims that justify a multi-year commitment. Manufacturer-sponsored clinical studies alone are insufficient for a category where implant survivorship at 10 and 15 years is the relevant performance horizon, not 12-month outcomes.

Finally, any vendor bundling bone void fillers, allograft, or growth factors into an implant contract as a package item should be asked to unbundle and document each product's regulatory pathway separately. Some biologics in this category are regulated as Class III biologics by FDA's Center for Biologics Evaluation and Research (CBER), not CDRH—a materially different regulatory standard that requires independent evaluation before procurement.

Questions to ask vendors

What is the current FDA 510(k) or PMA clearance number for each implant line in the proposed contract, and what predicate device was cited? Please provide the complete 510(k) summary including performance testing data.
What are your GPO tier pricing levels, volume rebate thresholds, and price adjustment terms for a multi-year contract—and will you include a most-favored-nation pricing clause?
What is the documented 10- and 15-year survivorship for this implant system from an independent national registry such as AJRR, disaggregated by bearing surface and fixation method?
How many loaner instrument sets can you guarantee per week for our projected case volume, and what is your contractual commitment for next-day emergency restocking of trauma and revision implants?
If this implant requires your robotic platform, what are the full capital cost, annual service contract terms, and implant exclusivity obligations—and is there a 510(k)-cleared manual instrumentation alternative?
Do your manufacturing facilities hold current ISO 13485:2016 certification, and can you provide a biological evaluation summary per ISO 10993-1 for each implant material or bearing surface proposed?

Alternatives

The strategic choice between GPO contracting and direct negotiation is not binary—it depends on volume. Purchasing through an established GPO provides benchmark pricing and contract compliance infrastructure that smaller facilities cannot replicate independently. However, facilities performing 500 or more annual joint replacements should model direct negotiation alongside GPO pricing; at that volume, manufacturer incentive to offer below-GPO pricing is real.

Reference pricing—setting a fixed maximum the hospital will pay per implant construct—has demonstrated cost reduction in total hip arthroplasty without compromising clinical outcomes [S3]. This strategy requires hospital-physician co-management governance and VAC authority to enforce the cap, but it shifts the negotiating posture fundamentally: the vendor must meet the price, or the surgeon must justify the premium.

On the inventory model question, consignment suits high-acuity, variable-case-mix settings like trauma centers where implant consumption is unpredictable; purchased par-level inventory suits high-volume, standardized elective programs where case mix is predictable and carrying cost is manageable. A hybrid—purchased primary, consignment revision and specialty—is common at high-volume orthopedic programs.

One point warrants an unambiguous statement: reprocessed or remanufactured permanent orthopedic implants are not a recognized FDA-cleared procurement pathway. Any vendor offering "reprocessed" permanent implants should be disqualified immediately. Reprocessing applies to certain reusable surgical instruments—not to implant constructs designed for permanent in-body use. The single-use sterile designation is not a marketing convention; it is a regulatory classification with patient safety implications.

Sources

Browse vendors in

Orthopedic Implants

MedSource publishes neutral guidance. We do not accept payment from vendors to influence the content of articles. AI-generated articles are reviewed for factual accuracy but cited sources should be the primary reference for procurement decisions.